Compare IDYA & UPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDYA | UPST |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 2019 | 2020 |
| Metric | IDYA | UPST |
|---|---|---|
| Price | $39.98 | $27.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 16 |
| Target Price | ★ $52.86 | $45.84 |
| AVG Volume (30 Days) | 701.7K | ★ 4.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.90 | ★ 131.25 |
| EPS | N/A | ★ 0.10 |
| Revenue | $218,710,000.00 | ★ $1,043,857,000.00 |
| Revenue This Year | N/A | $34.45 |
| Revenue Next Year | $201.05 | $32.64 |
| P/E Ratio | ★ N/A | $286.80 |
| Revenue Growth | ★ 3024.43 | 63.99 |
| 52 Week Low | $23.23 | $23.97 |
| 52 Week High | $42.68 | $71.38 |
| Indicator | IDYA | UPST |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 38.89 |
| Support Level | $33.57 | $25.32 |
| Resistance Level | $39.93 | $34.80 |
| Average True Range (ATR) | 1.35 | 1.62 |
| MACD | 0.09 | -0.19 |
| Stochastic Oscillator | 59.26 | 1.25 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).